- Forte, Maria Florencia
- Oliva, Vincenzo
- De Prisco, Michele
- Garriga, Marina
- Bitanihirwe, Byron
- Alameda, Luis
- Amoretti, Silvia
- Ramos-Quiroga, Josep Antoni
Obstetric complications; Psychopathology; Schizophrenia, Complicaciones obstétricas; Psicopatología; Esquizofrenia, Complicacions obstètriques; Psicopatologia; Esquizofrènia, Schizophrenia (SZ) is a severe mental health condition involving gene-environment interactions, with obstetric complications (OCs) conferring an elevated risk for the disease. Current research suggests that OCs may exacerbate SZ symptoms. This study conducted a systematic review and meta-analysis to comprehensively evaluate differences in psychopathology between individuals with and without exposure to OCs in relation to SZ and related disorders. We systematically searched PubMed, PsycINFO, and SCOPUS to identify eligible studies. A total of 4091 records were retrieved through systematic and citation searches. 14 studies were included in the review, and 12 met the criteria for meta-analysis, involving 2992 patients. The analysis revealed that SZ patients who had been exposed to OCs exhibited significantly higher levels of positive symptoms (SMD=0.10, 95 %CI=0.01,0.20; p=0.03), general psychopathology (SMD=0.37, 95 %CI=0.22,0.52; p<0.001), total clinical symptomatology (SMD=0.44, 95 %CI=0.24,0.64; p<0.001) and depressive symptoms (SMD=0.47, 95 %CI=0.09,0.84; p=0.01). No significant differences were found in negative symptomatology and functioning. Our results suggest that OCs are not only associated with an increased risk of developing psychosis but with more severe symptomatology., This study is part of the project PI20/00661 (C. García-Rizo) and PI24/00196 (C. Garcia-Rizo and G. Mezquida) funded by the Carlos III Health Institute (ISCIII) and co-financed by the European Union, Centro de Investigación Biomédica en Red de salud Mental, CIBERSAM, CERCA Program / Generalitat de Catalunya And Secretaria d′Universitats i Recerca del Departament d′Economia I Coneixement (2017SGR1355). G. Mezquida is a Serra Húnter Fellow, within the Tenure-elegible Lecturer Serra Hunter program (UB-LE-212–024, Generalitat de Catalunya). M. F. Forte received the support of “Contratos predoctorales de formación en investigación en salud" (PFIS22) (FI22/00185) from the Instituto de Salud Carlos III (ISCIII) with European funds from the Recovery, Transformation and Resilience Plan, by virtue of the Resolution of the Directorate of the Carlos III Health Institute, O.A., M.P. of December 14, 2022, granting Predoctoral Research Training Contracts in Health (PFIS Contracts). Funded by the European Union NextGenerationEU. S. Amoretti has been supported by Sara Borrell doctoral programme (CD20/00177) and M-AES mobility fellowship (MV22/00002), from the Instituto de Salud Carlos III (ISCIII), and co-funded by European Social Fund “Investing in your future”. E. Vieta thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI18/00805; PI21/00787) integrated into the Plan Nacional de I+D+I and co-financed by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER); CIBERSAM; and the Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya to the Bipolar Disorders Group (2021 SGR 1358) and the project SLT006/17/00357, from PERIS 2016–2020 (Departament de Salut). CERCA Programme/Generalitat de Catalunya. M. Garriga thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI21/00340) integrated into the Plan Nacional de I+D+I and co-financed by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER); CIBERSAM; and the Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya to the Bipolar Disorders Group (2021 SGR 1358). CERCA Programme/Generalitat de Catalunya. J.A. Ramos-Quiroga thanks the suport of the CIBERSAM; Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya to the Psychiatry, Mental Health and Addictions Group (2021 SGR 00840). I. Baeza thanks the Spanish Ministry of Science, Innovation and Universities and Instituto de Salud Carlos III (PI21/0391) co-funded by the European Union, the National Drugs Plan (2022 I053) and Fundación Alicia Koplowitz., We would like to thank the Carlos III Healthcare Institute, the Spanish Ministry of Science, Innovation and Universities, the European Regional Development Fund (ERDF/FEDER) (PI08/0208, PI11/00325, PI14/00612, PI14/00753, PI20/00661, and PI24/00196); CIBERSAM; CERCA Program; Government of Catalonia, the Secretariat of Universities and Research of the Department of Enterprise and Knowledge (2021 SGR 01120), the Institut de Neurociències, Universitat de Barcelona, UBNeuro, and the Serra-Hunter Programme, Government of Catalonia. This work was also supported by La Marató-TV3 Foundation grants 202234–32 (to S. Amoretti); 202234–30 (to E. Vieta); 202234–30 (to A. Gonzàlez-Segura), 202225–30 (to R. Penadés). IB thanks Pons Bartran legacy (FCRB_IPB2–2023), and CGR thanks the Maria i Nuria Cunillera legacy (FCRB_CU1_2024) for the support.